← back to search

Mark Lew

LAC+USC Medical Center ·
Area of research
Neurology · Cellular and Molecular Neuroscience
Research interest
Research interests include Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments, Botulinum Toxin and Related Neurological Disorders, and Genetic Neurodegenerative Diseases.
h-index
42
citations
6,659
works
145
NIH funding
primary concept
email

Recent publications

Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study
Journal of Parkinson s Disease 2025cited by 15position: middledoi
Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor
Tremor and Other Hyperkinetic Movements 2020cited by 69position: middledoi
Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults
JAMA Neurology 2020cited by 68position: middledoi
Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease
Movement Disorders 2018cited by 93position: middledoi
The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension
Journal of Neurology 2017cited by 440position: middledoi
CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP
Neurology 2017cited by 107position: middledoi
Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry
Journal of the Neurological Sciences 2017cited by 38position: middledoi
Progression of brain atrophy in PSP and CBS over 6 months and 1 year
Neurology 2016cited by 97position: middledoi
Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease
JAMA 2015cited by 239position: middledoi
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
JAMA Neurology 2014cited by 389position: middledoi
Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: Final 12‐month, open‐label results
Movement Disorders 2014cited by 237position: middledoi
Accuracy and Sensitivity of Parkinsonian Disorder Diagnoses in Two Swedish National Health Registers
Neuroepidemiology 2012cited by 70position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Alberto J. Espay · University of Cincinnati5 papers (2014–2025)Stuart Isaacson · Vion Pharmaceuticals (United States)3 papers (2017–2025)Peter A. LeWitt · Henry Ford Health System2 papers (2017–2025)Krai Chatamra · AbbVie (United States)2 papers (2014–2018)Khashayar Dashtipour · University of California System2 papers (2020–2025)Weining Robieson · AbbVie (United States)2 papers (2014–2018)Coleen Hall · AbbVie (United States)2 papers (2014–2018)Richard Trosch · Rush University Medical Center2 papers (2017–2020)Janet Benesh · AbbVie (United States)2 papers (2014–2018)Hubert H. Fernandez · Universidade Federal do Rio Grande do Sul2 papers (2014–2018)David G. Standaert · University of Alabama at Birmingham2 papers (2014–2018)Victor S.C. Fung · The University of Sydney2 papers (2014–2018)Per Odin · Lund University1 papers (2014–2014)Rajesh Pahwa · University of Kansas1 papers (2025–2025)Roy Freeman · Beth Israel Deaconess Medical Center1 papers (2017–2017)Satish R. Raj · Museo Egizio1 papers (2017–2017) · 1 papers (2025–2025)James T. Boyd · Neurological Surgery1 papers (2018–2018)Fabian Klostermann · Freie Universität Berlin1 papers (2014–2014)Charles H. Adler · WinnMed1 papers (2017–2017)